1. J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138: 2101 - 14.

2. Johns L.E., Houlston R.S. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2992 - 3003.

3. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009; 10: 353 - 8.

4. Huxley R.R., Ansary-Moghaddam A., Clifton P. et al. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: A quantitative overview of the epidemiological evidence. Int J Cancer 2009; 125: 171 - 80.

5. Watson A.J.M., Collins P.D. Colon cancer: a civilization disorder. Dig Dis 2011; 29: 222 - 8.

6. Meyerhardt J.A., Catalano P.J., Haller D.G. et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21: 433 - 40.

7. A., Aagnes B., Robsahm T.E. et al. Subsite-specific dietary risk factors for colorectal cancer: a review of cohort studies. J Oncol 2013; 2013: 703854.

8. Theodoratou E., Farrington S.M., Tenesa A. et al. Associations between dietary and lifestyle risk factors and colorectal cancer in the Scottish population. Eur J Cancer Prev 2014; 23: 8 - 17.

9. Rasool S., Kadla S.A., Rasool V., Ganai B.A. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumor Biol 2013; 34: 2469 - 76.

10. Esposito K., Chiodini P., Capuano A. et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013; 44: 634 - 47.

11. Larsson S.C., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679 - 87.

12. Raskov H., Pommergaard H.C., Burcharth J., Rosenberg J. Colorectal carcinogenesis - update and perspectives. World J Gastroenterol 2014; 20: 18151 - 64.

13. Donohoe C., O'Farrell N., Doyle S., Reynolds J. The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol 2014; 7: 38 - 50.

14. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИЦ радиологии Минздрава России, 2020. 252 с.

15. Speights V.O., Johnson M.W., Stoltenberg P.H. et al. Colorectal cancer: current trends in initial clinical manifestations. South Med J 1991; 84(5): 575 - 8.

16. Schmoll H.J., Van Cutsem E., Stein A. et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479 - 516.

17. Цуканов А.С., Шелыгин Ю.А., Фролов С.А. и др. Рекомендации по отбору пациентов для молекулярно-генетической диагностики синдрома Линча. Методические рекомендации. М., 2019.

18. Liu Z., Zhang Y., Niu Y. et al. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS One 2014; 9(8): e103910.

19. Langevin J.M., Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study. Am J Surg 1984; 147(3): 330 - 3.

20. Mulder S.A., Kranse R., Damhuis R.A. et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol 2011; 35(5): 442 - 7.

21. Finan P.J., Ritchie J.K., Hawley P.R. Synchronous and metachronous carcinomas of the colon and rectum. Br J Surg 1987; 74: 945 - 7.

22. Computed tomographic colonography compared with colonoscopy or barium enema for diagnosis of colorectal cancer in older symptomatic patients: two multicentre randomised trials with economic evaluation (the SIGGAR trials). Health Technol Assess 2015; 19(54): 1 - 134.

23. Floriani I., Torri V., Rulli E. et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31(1): 19 - 31.

24. Nordholm-Carstensen A., P.A., Jorgensen L.N. et al. Indeterminate pulmonary nodules at colorectal cancer staging: a systematic review of predictive parameters for malignancy. Ann Surg Oncol 2013; 20(12): 4022 - 30.

25. Sun S., Yang C., Huang Z. et al. Diagnostic value of magnetic resonance versus computed tomography colonography for colorectal cancer: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2018; 97(22): e10883.

26. Brown G., Radcliffe A.G., Newcombe R.G. et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003; 90(3): 355 - 64.

27. Herrmann J., Lerman A., Sandhu N.P. et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 2014; 89(9): 1287 - 306.

28. Starck M., Bohe M., Simanaitis M., Valentin L. Rectal endosonography can distinguish benign rectal lesions from invasive early rectal cancers. Colorectal Dis 2003; (3): 246 - 50.

29. Lee E.J., Lee J.B., Lee S.H. et al. Endoscopic submucosal dissection for colorectal tumors--1,000 colorectal ESD cases: one specialized institute"s experiences. Surg Endosc 2013; 27(1): 31 - 9.

30. Diagnostic value of endorectal ultrasound in preoperative assessment of lymph node involvement in colorectal cancer: A meta-analysis. Asian Pac J Cancer Prev 2015; 16: 3485 - 91.

31. Choi S.H., Kim S.Y., Park S.H. et al. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: systematic review and meta-analysis. J Magn Reson Imaging 2018; 47: 1237-50.

32. Ko Y., Kim J., Park J.K. et al. Limited detection of small (<= 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection. PloS One 2017; 12(12): e0189797.

33. Ribas Y., Hotouras A., Wexner S.D., D"Hoore A. Shared decision-making and informed consent process in rectal cancer treatment: weighing up oncological and functional outcomes. Colorectal Dis 2016; 18(1): 9 - 12.

34. Roth E.S., Fetzer D.T., Barron B.J. et al. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. BMC Cancer 2009; 9: 274.

35. Augestad K.M., Bakaki P.M., Rose J. et al. Metastatic spread pattern after curative colorectal cancer surgery. A retrospective, longitudinal analysis. Cancer Epidemiol 2015; 39(5): 734 - 44.

36. Daza J.F., Solis N.M., Parpia S. et al. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. Eur J Surg Oncol 2019; 45(8): 1341 - 8.

37. Muntean V., Oniu T., Lungoci C. et al. Staging laparoscopy in digestive cancers. J Gastrointestin Liver Dis 2009; 18(4): 461 - 7.

38. De Marco M.F., Janssen-Heijnen M.L., van der Heijden L.H., Coebergh J.W. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 2000; 36(1): 95 - 9.

39. Федянин М.Ю., Трякин А.А., Тюляндин С.А. Потенциальные предикторы эффективности анти-EGFR-терапии при метастатическом раке толстой кишки. Онкологическая колопроктология 2013; (2): 21 - 30.

40. Khattak M.A., Martin H., Davidson A., Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 2015; 14(2): 81 - 90. DOI: 10.1016/j.clcc.2014.12.011.

41. Pietrantonio F., Petrelli F., Coinu A., et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51(5): 587 - 94.

42. Yoshino T., Arnold D., Taniguchi H. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 2018; 29(1): 44 - 70.

43. Hurlstone D.P., Cross S.S., Drew K. et al. An evaluation of colorectal endoscopic mucosal resection using high-magnification chromoscopic colonoscopy: a prospective study of 1000 colonoscopies. Endoscopy 2004; 36(6): 491 - 8.

44. Chiba H., Tachikawa J., Kurihara D. et al. Safety and efficacy of simultaneous colorectal ESD for large synchronous colorectal lesions. Endosc Int Open 2017; 5(7): E595 - 602.

45. Lee E.J., Lee J.B., Lee S.H. et al. Endoscopic submucosal dissection for colorectal tumors--1,000 colorectal ESD cases: one specialized institute"s experiences. Surg Endosc 2013; 27(1): 31 - 9.

46. Landmann R.G., Weiser M.R. Surgical management of locally advanced and locally recurrent colon cancer. Clin Colon Rectal Surg 2005; 18(3): 182 - 9.

47. Brandi G., De Lorenzo S., Nannini M. et al. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519.

48. Keikes L., Koopman M., Tanis P.J. et al. Evaluating the scientific basis of quality indicators in colorectal cancer care: a systematic review. Eur J Cancer 2017; 86: 166 - 77.

49. Yin Z., Liu C., Chen Y. et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed? Hepatology 2013; 57(6): 2346 - 57.

50. Feng Q., Wei Y., Zhu D. et al. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable - a meta-analysis. PLoS One 2014; 9(8): e104348.

51. Garden O.J., Rees M., Poston G.J. et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 (Suppl. 3): iii 1 - 8.

52. Hughes K.S., Simon R., Songhorabodi S. et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100(2): 278 - 84.

53. Richardson B., Preskitt J., Lichliter W. et al. The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? Am J Surg 2016; 211(1): 46 - 52.

54. Chow F.C., Chok K.S. Colorectal liver metastases: an update on multidisciplinary approach. World J Hepatol 2019; 11(2): 150 - 72.

55. Brandi G., De Lorenzo S., Nannini M. et al. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519 - 33.

56. Primrose J., Falk S., Finch-Jones M. et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15(6): 601 - 11.

57. Geissler M., Riera-Knorrenschild J., Tannapfel A. et al. mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109). J Clin Oncol 2018; (Suppl. 15): 3509.

58. Cremolini C., Loupakis F., Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16(13): 1306 - 15.

59. Baraniskin A., Buchberger B., Pox C. et al. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Eur J Cancer 2019; 106: 37 - 44.

60. Cetinkaya E., Dogrul A.B., Tirnaksiz M.B. Role of self expandable stents in management of colorectal cancers. World J Gastrointest Oncol 2016; 8(1): 113 - 20.

61. Goldberg R.M., Fleming T.R., Tangen C.M. et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med 1998; 129(1): 27 - 35.

62. Bowne W.B., Lee B., Wong W.D. et al. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. Dis Colon Rectum 2005; 48(5): 897 - 909.

63. K.F., Matos D., P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev 2011; (9): CD001544.

64. Lacy A.M., J.C., Delgado S. et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002; 359(9325): 2224 - 9.

65. Veldkamp R., Kuhry E., Hop W.C. et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 2005; 6(7): 477 - 84.

66. Guillou P.J., Quirke P., Thorpe H. et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365(9472): 1718 - 26.

67. Fleshman J., Sargent D.J., Green E. et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg 2007; 246(4): 655 - 62.

68. De Salvo G.L., Gava C., Pucciarelli S., Lise M. Curative surgery for obstruction from primary left colorectal carcinoma: primary or staged resection? Cochrane Database Syst Rev 2004; (2): CD002101.

69. Khot U.P., Lang A.W., Murali K., Parker M.C. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89(9): 1096 - 120.

70. Meyer F., Marusch F., Coch A. et al. Emergency operation in carcinomas of the left colon: value of Hartmann"s procedure. Tech Coloproctol 2004; 8 (Suppl. 1): S226 - 9.

71. Iveson T., Sobrero A.F., Yoshino T. et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). J Clin Oncol 2019; (Suppl.): 3501.

72. Федянин М.Ю. Современная клиническая и молекулярно-биологическая платформа лечения пациентов раком толстой кишки: дис. ... д-ра мед. наук. М., 2018. 414 с.

73. Grothey A., Sobrero A.F., Shields A.F. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378: 1177 - 88.

74. Alberts S.R., Sargent D.J., Nair S. et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383 - 93.

75. Allegra C.J., Yothers G., O'Connell M.J. et al. Bevacizumab in stage II - III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013; 31: 359 - 64.

76. Seymour M.T., Maughan T.S., Ledermann J.A. et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143 - 52.

77. Cunningham D., Sirohi B., Pluzanska A. et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 244 - 50.

78. Ackland S.P., Jones M., Tu D. et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93: 1236 - 43.

79. Jonker D., Rumble R.B., Maroun J. Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first-and second-line treatment of advanced colorectal cancer. Curr Oncol 2006; 13(5): 173.

80. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229 - 37.

81. Van Helden E.J., Menke-van der Houven van Oordt C.W., Heymans M.W. et al. Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer Metastasis Rev 2017; 36(2): 395 - 406.

82. Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509 - 20.

83. Overman M.J., McDermott R., Leach J.L. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18(9): 1182 - 91.

84. Overman M.J., Lonardi S., Wong K.Y.M. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36(8): 773 - 9.

85. Wirapati P., Pomella V., Vandenbosch B. et al. Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol 2017; (Suppl. 15): 3538.

86. Kopetz S., McDonough S.L., Morris V.K. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017; 35 (Suppl. 4): 520.

87. Corcoran R.B., Andre T., Atreya C.E. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF^V600E-mutant colorectal cancer. Cancer Discov 2018; 8(4): 428 - 43.

88. Hansen R., Quebbeman E., Ausman R. et al. Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: Results in 91 patients. J Surg Oncol 1989; 40(3): 177 - 81.

89. Costi R., Leonardi F., Zanoni D. et al. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602 - 21.

90. Bayraktar B., Ozemir I.A., Kefeli U. et al. Colorectal stenting for palliation and as a bridge to surgery: a 5-year follow-up study. World J Gastroenterol 2015; 21(31): 9373 - 9.

91. Saif M.W., Siddiqui I.A.P., Sohail M.A. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 2009; 29(5): 369 - 77.

92. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatment related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013; 92: 715 - 27.

93. Hijazia Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017; 39: 156 - 62.

94. Gillis C., Li C., Lee L. et al. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology 2014; 121: 937 - 47.

95. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015; 22(13): 4117 - 23.

96. Li P., Fang F., Cai J.X. et al. Fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for colorectal malignancy: a meta-analysis. World J Gastroenterol 2013; 19: 9119 - 26.

97. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010; 210(4): 491 - 5.

98. Soh J.S., Lee H.J., Jung K.W. et al. The diagnostic value of a digital rectal examination compared with high-resolution anorectal manometry in patients with chronic constipation and fecal incontinence. Am J Gastroenterol 2015; 110: 1197 - 204.

99. Lundby L., Duelund-Jakobsen J. Management of fecal incontinence after treatment for rectal cancer. Curr Opin Support Palliat Care 2011; 5: 60 - 4.

100. Sokol E.R. Management of fecal incontinence - focus on a vaginal insert for bowel control. Med Devices (Auckl) 2016; 9: 85 - 91.

101. Benezech A., Bouvier M., Vitton V. Faecal incontinence: current knowledges and perspectives. World J Gastrointest Pathophysiol 2016; 7(1): 59 - 71.

102. Kraljevi N. Rehabilitation for colorectal cancer. Review. Libri Oncol 2013; 41(1 - 3): 87 - 92.

103. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3: 961 - 8.

104. Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018; 124(3): 546 - 54.

105. Wonga C.L., Lee H.H.C., Chang S.C. Colorectal cancer rehabilitation review. J Cancer Res Pract 2016; 3(2): 31 - 3.

106. Wolin K.Y., Yan Y., Colditz G.A. et al. Physical activity and colon cancer prevention: a meta-analysis Br J Cancer 2009; 100: 611 - 6.

107. Jeon J., Sato K., Niedzwiecki D. et al. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: findings from CALGB 89903/Alliance. Clin Colorectal Cancer 2013; 12(4): 233 - 8.

108. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol 2017; 24(4): e290 - 315.

109. Carmichael J.C., Keller D.S., Baldini G. et al. Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and Society of American Gastrointestinal and Endoscopic Surgeons. Dis Colon Rectum 2017; 60(8): 761 - 84.

110. Fujino S., Miyoshi N., Ohue M., Takahashi Y. Prediction model and treatment of high-output ileostomy in colorectal cancer surgery. Mol Clin Oncol 2017; 7(3): 468 - 72.

111. Guo Y., Xiong B.H., Zhang T. et al. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. Cancer Invest 2016; 34(2): 94 - 104.

112. Marques R.P., Duarte G.S., Sterrantino C. et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2017; 118: 54 - 62.

113. Guo Y., Shi M., Shen X. et al. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. Clin Colorectal Cancer 2014; 13(2): 110 - 8.

114. Zhao X.D., Cai B.B., Cao R.S., Shi R.H. et al. Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis. World J Gastroenterol 2013; 19(33): 5565.

115. Stillwell A.P., Buettner P.G., Ho Y.H. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010; 34(4): 797 - 807.

116. Song X.J., Liu Z.L., Zeng R. et al. A meta-analysis of laparoscopic surgery versus conventional open surgery in the treatment of colorectal cancer. Medicine 2019; 98(17): e15347.

117. Da Silva W.C., de Araujo V.E., e Abreu Lima E.M. et al. Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: a systematic review and meta-analysis. BioDrugs 2018; 32(6): 585 - 606.

118. Visser W.S., Te Riele W.W., Boerma D. et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Ann Coloproctol 2014; 30(3): 109 - 14.

119. Efthimiadis C., Basdanis G., Zatagias A. et al. Manometric and clinical evaluation of patients after low anterior resection for rectal cancer. Tech Coloproctol 2004; 8(1): s205 - 7.

120. Jeffery M., Hickey B.E., Hider P.N. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2019; (9): CD002200.

121. Park J.G., Vasen H.F., Park K.J. et al. Amsterdam Criteria: The International Collaborative Group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424 - 5.

122. Syngal S., Fox E.A., Eng C. et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37(9): 641 - 5.

123. Moreira L., Balaguer F., Lindor N. et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308(15): 1555 - 65.

124. Therkildsen C., Bergmann T.K., Henrichsen-Schnack T., Ladelund S., Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014; 53(7): 852 - 64.

125. Zabaleta J., Iida T., Falcoz P.E. et al. Individual data meta-analysis for the study of survival after pulmonary metastasectomy in colorectal cancer patients: A history of resected liver metastases worsens the prognosis. Eur J Surg Oncol 2018; 44(7): 1006 - 12.

126. Chu E., DeVita V.T. Jr. Physicians' Cancer Chemotherapy Drug Manual 2013. Jones & Bartlett Learning, LLC, an Ascend Learning Company, 2013.

127. Fernandes G.D.S., Braghiroli M.I., Artioli M. et al. Combination of irinotecan, oxaliplatin and 5-fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients. J Gastrointest Cancer 2018; 49(4): 470 - 5.

128. Xu R.H., Muro K., Morita S. et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19(5): 660 - 71.

129. Fernandez-Plana J., Pericay C., Quintero G. et al. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). BMC Cancer 2014; 14: 865.

130. Bekaii-Saab T.S. et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20(8): 1070 - 82.

131. Wang X., Zheng Z., Sun Y. et al. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J Gastrointest Oncol 2019; 11(4): 335 - 47. DOI: 10.4251/wjgo.v11.i4.335.

132. Meric-Bernstam F., Hurwitz H., Raghav K.P.S. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019; 20(4): 518 - 30. DOI: 10.1016/S1470-2045(18)30904-5.

133. Sartore-Bianchi A., Trusolino L., Martino C. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17(6): 738 - 46. DOI: 10.1016/S1470-2045(16)00150-9.

134. Li Q., Liu Y., Zhang H.M. et al. Influence of DPYD Genetic Polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract 2014; 2014: 827989.

135. Zech C., Korpraphong P., Huppertz A. et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg 2014; 101(6): 613 - 21.

136. Seligmann J.F., FOxTROT Collaborative Group. FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC). J Clin Oncol 2020; 38 (Suppl. 15): 4013. DOI: 10.1200/JCO.2020.38.15_suppl.4013.

137. T., Shiu K.K., Kim T.W. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383(23): 2207 - 18. DOI: 10.1056/NEJMoa2017699.

138. Lenz H.J., Lonardi S., Zagonel V. et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. J Clin Oncol 2019; 37 (Suppl. 15): 3521. DOI: 10.1200/JCO.2019.37.15_suppl.3521.

139. Sobrero A.F., Andre T., Meyerhardt J.A. et al. Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. J Clin Oncol 2020; 38 (Suppl. 15): 4004. DOI: 10.1200/JCO.2020.38.15_suppl.4004.

140. Andre T., Bonni C., Navarro M. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109 - 16.

141. Kuebler J.P., Wieand H.S., O'Connell M.J. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198 - 204.

142. Kanemitsu Y., Shitara K., Mizusawa J. et al. A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS). J Clin Oncol 2020; 38 (Suppl. 4): 7. DOI: 10.1200/JCO.2020.38.4_suppl.7.

143. Cheeseman S.L., Joel S.P., Chester J.D. et al. A regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87(4): 393 - 9. DOI: 10.1038/sj.bjc.6600467.

144. Venook A.P., Niedzwiecki D., Lenz H.-J. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (FOLFOX) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum [abstract]. ASCO Meeting Abstracts 2014; 32: LBA3.

145. Munemoto Y., Nakamura M., Takahashi M. et al. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer 2019; 119: 158 - 67. DOI: 10.1016/j.ejca.2019.07.006.

146. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D. et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23(15): 3502 - 8.

147. Garcia-Carbonero R., Obermannova R., Bodoky G. et al. Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Ann Oncol 2015; 26: 115.

148. Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499 - 506.

149. Cunningham D., Lang I., Marcuello E. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14(11): 1077 - 85.

150. Guo W., Zhang X., Wang Y. et al. FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: an open, multicenter, prospective, randomized controlled phase III clinical study. J Clin Oncol 2020; 38 (Suppl. 15): 4038. DOI: 10.1200/JCO.2020.38.15_suppl.4038.

151. Bennouna J., Hiret S., Bertaut A. et al. Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol 2019; 5(1): 83 - 90. DOI: 10.1001/jamaoncol.2018.4465.

152. Hecht J.R., Cohn A., Dakhil S. et al. SPIRITT: a randomized, multicenter, phase ii study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 2015; 14(2): 72 - 80. DOI: 10.1016/j.clcc.2014.12.009.

153. Ciardiello F., Normanno N., Martinelli E. et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 2016; 27(6): 1055 - 61. DOI: 10.1093/annonc/mdw136.

154. O., M.B., Sakin A. et al. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol 2019; 83(1): 115 - 22. DOI: 10.1007/s00280-018-3713-6.

155. Федянин М.Ю., Полянская Е.М., Эльснукаева Х.Х. и др. Метаанализ исследований по сравнению эффективности режимов FOLFOXIRI и FOLFOX или FOLFIRI с таргетной терапией при метастатическом раке толстой кишки с мутацией в гене BRAF. Медицинский совет 2020; (20): 125 - 32. DOI: 10.21518/2079-701X-2020-20-125-132.

156. Kopetz S., Guthrie K.A., Morris V.K. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol 2021; 39(4): 285 - 94. DOI: 10.1200/JCO.20.01994.

157. Corcoran R.B., Atreya C.E., Falchook G.S. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015; 33: 4023 - 31.

158. Klute K., Garrett-Mayer E., Halabi S. et al. Cobimetinib plus vemurafenib (C + V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study. J Clin Oncol 2020; 38 (Suppl. 4): 122. DOI: 10.1200/JCO.2020.38.4_suppl.122.

159. Allegra C.J. et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. Journal of Clinical Oncology 2009; 27(20) 3385.

160. Peng J. et al. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience. Cancer Communications 2019; 39(1): 1 - 12.

161. Sharif S. et al. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer investigation 2008; 26(9): 956 - 63.

162. Demir L., Somal I., Oktay Tarhan M., Erten C. et al. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer. J BUON 2011; 16(4): 682 - 8.

163. Sorbye H., Glimelius B., Berglund A. et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31 - 8.

164. Gallois C., Shi Q., Meyers J.P. et al. Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials. Journal of Clinical Oncology 2022; 40 (Suppl. 4): 11.

165. Трякин А.А., Бесова Н.С., Волков Н.М., Гладков С.А. и др. Злокачественные опухоли. Практические рекомендации RUSSCO #3s2, 2021; 11(1). DOI: 10.18027/2224-5057-2021-11-3s2-01.

166. Matsuda A. et al. Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a meta-analysis. Anticancer Research 2020; 40(6): 3469 - 76.

167. Cohen R., Meurisse A., Pudlarz T. et al. One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study. Journal of Clinical Oncology 2022; 40 (Suppl. 4): 13.

168. Winther S.B., P., Berglund A. et al. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer 2017; 17: 548.

169. Sartore-Bianchi A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. The Lancet Oncology 2016; 17(6): 738 - 46.

170. Tabernero J., Yoshino T., Cohn A.L. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16(5): 499 - 508. DOI: 10.1016/S1470-2045(15) 70127-0.

171. Cunningham D., Lang I., Marcuello E., Lorusso V. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14(11): 1077 - 85.

172. Hofheinz R., Wenz F., Post S. et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial. J Clin Oncol 2009; 27(15S): 4014.

173. Feliu J. et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. British journal of cancer 2010; 102(10): 1468 - 73.

174. Bang Y.H. et al. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Scientific Reports 2021; 11(1): 1 - 9.

175. Modest D.P., Martens U.M., Riera-Knorrenschild J. et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol 2019; 37(35): 3401 - 11.

176. Федянин М.Ю., Полянская Е.М., Трякин А.А. и др. Влияние стартовой дозы регорафениба на общую выживаемость пациентов с метастатическим раком толстой кишки: систематический обзор и метаанализ. Современная онкология 2019; 21(3): 10 - 5. DOI: 10.26442/18151434.2019.3.19065.

177. O., M.B., Sakin A., Demir T. et al. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol 2019; 83(1): 115 - 22. DOI: 10.1007/s00280-018-3713-6.

178. Gundgaard M.G., Soerensen J.B., Ehrnrooth E. Third-line therapy for metastatic colorectal cancer. Cancer chemotherapy and pharmacology 2008; 61(1): 1 - 13.

179. Walter T. et al. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. Journal of cancer research and clinical oncology 2020; 146(10): 2575 - 87.

180. Fedyanin M., Elsnukaeva H., Demidova I. et al. Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice. Annals of Oncology 2021; 32 (Suppl. 5): S530 - 82.

181. Yaeger R. et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clinical cancer research 2015; 21(6): 1313 - 20.

182. Hyman D.M. et al. Vemurafenib in multiple non-melanoma cancers with BRAF V600 mutations. New England Journal of Medicine 2015; 373(8): 726 - 36.

183. Wu Z. et al. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF (V600E)-mutant colorectal cancer cells. Acta Biochimica et Biophysica Sinica 2018; 50(4): 355 - 61.

184. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Злокачественные опухоли 2021; 11(3s2-2): 25 - 38.

185. Багрова С.Г. и др. Использование остеомодифицирующих агентов (ОМА) для профилактики и лечения патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли 2021; 10(3s2-2): 35 - 44.

186. Сакаева Д.Д. и др. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Злокачественные опухоли 2021; 11(3s2-2): 55 - 63.

187. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Клинические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Злокачественные опухоли 2021; 10(3s2-2): 52 - 65.

188. Виценя М.В. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли 2021; 10(3s2-2): 66 - 87.

189. Королева И.А. и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Злокачественные опухоли 2021; 11(3S2-2): 99 - 113.

190. Сытов А.В. и др. Практические рекомендации по нутритивной поддержке онкологических больных. Злокачественные опухоли 2021; 11(3s2-2): 114 - 22.

191. Громова Е.Г. и др. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов. Злокачественные опухоли 2021; 11(3s2-2): 132 - 44.

192. Сомонова О.В. и др. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли 2021; 11(3S2-2): 145 - 55.

193. Буйденок Ю.В. Рекомендации по лечению последствий экстравазации противоопухолевых препаратов. Злокачественные опухоли 2021; 10(3s2-2): 141 - 47.

194. Проценко С.А. и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли 2021; 11(3s2-2): 187 - 223.

195. Анемия при злокачественных новообразованиях. Клинические рекомендации Министерства здравоохранения Российской Федерации. Электронный ресурс: https://cr.minzdrav.gov.ru/schema/624_1.

196. WHO Classification of Tumours Editorial Board. Digestive system tumors (5th edition). IARC; Lyon, 2019.

197. Jauhri M. et al. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing - based cohort study. Tumor Biology 2017; 39(2): 1010428317692265.

198. Brannon A.R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome biology 2014; 15(8): 1 - 10.

199. Loughrey M.B., Quirke P., Shepherd N. Dataset for colorectal cancer histopathology reports. The Royal College of Pathologists, 2014.

200. Динаева Э.А. и др. Значение эмпэгфилграстима в интенсивных режимах терапии опухолей ЖКТ//Доклад на сессии "Отечественные исследования в онкологии". Конференция RUSSCO "Опухоли ЖКТ", 15 апреля 2022.

201. Китагава Ю., Осуми Х., Шинозаки Э., Юмико Ота Ю. и др. Клиническая полезность гранулоцитарного колониестимулирующего фактора, конъюгированного с полиэтиленгликолем (PEG-G-CSF), для профилактики тяжелой нейтропении у пациентов с метастатическим колоректальным раком, получавших FOLFOXIRI плюс бевацизумаб: одноцентровое ретроспективное исследование. БМК Рак 2020; 20: 358. DOI: 10.1186/s12885-020-06864-8.

202. Кроуфорд Д., Мур Д.С., Моррисон В.А., Дейл Д. Применение пегфилграстима в профилактических целях при нейтропении, вызванной химиотерапией, в США: обзор соблюдения настоящих рекомендаций по применению. Лечение рака и исследовательские коммуникации 2021; 29: 100466.

203. Lugli A. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern pathology 2017; 30(9): 1299 - 311.

204. Moehler M. et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. Journal of Clinical Oncology 2021; 39(9): 966.

205. 205. WHO Classification of Tumours Editorial Board. Digestive system tumors (5th edition). - IARC; Lyon, 2019

206. Jauhri M. et al. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing-based cohort study//Tumor Biology. - 2017. - Т. 39. - N. 2. - С. 1010428317692265.

207. Brannon A.R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions//Genome biology. - 2014. - Т. 15. - N. 8. - С. 1 - 10.

208. Modest D.P. et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: The randomized PANAMA trial (AIO KRK 0212)//Journal of Clinical Oncology. - 2022. - Т. 40. - N. 1. - С. 72 - 82.

209. Aparicio T. et al. Bevacizumab+ chemotherapy versus chemotherapy alone in elderly patients with un-treated metastatic colorectal cancer: A randomized phase II trial-PRODIGE 20 study results//Annals of Oncology. - 2018. - Т. 29. - N. 1. - С. 133 - 138.

210. Fujita K. et al. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer//World journal of gastroenterology. - 2015. - Т. 21. - N. 43. - С. 12234.

211. Dominik P Modest 1 2, Uwe M Martens 3, Jorge Riera-Knorrenschild, et al. FOLFOXIRI Plus Pani-tumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019 Dec 10; 37(35): 3401 - 3411.

212. Josep Tabernero 1, Takayuki Yoshino 2, Allen Lee Cohn, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol.

213. Freshwater T. et al. Evaluation of dosing strategy for pembrolizumab for oncology indications//Journal for immunotherapy of cancer. - 2017. - Т. 5. - N. 1. - С. 1 - 9.

214. Grothey A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial//The Lancet. - 2013. - Т. 381. - N. 9863. - С. 303 - 312.

215. Gundgaard M.G., Soerensen J.B., Ehrnrooth E. Third-line therapy for metastatic colorectal cancer//Cancer chemotherapy and pharmacology. - 2008. - Т. 61. - N. 1. - С. 1 - 13.

216. Walter T. et al. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer//Journal of cancer research and clinical oncology. - 2020. - Т. 146. - N. 10. - С. 2575 - 2587

217. 215. M. Fedyanin1, H. Elsnukaeva, I. Demidova, et al. 448P - Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice. Annals of Oncology (2021) 32 (suppl_5): S530 - S582. 10.1016/annonc/annonc698

218. 216. Wu Z. et al. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell ca-pacities in BRAF (V600E)-mutant colorectal cancer cells//Acta Biochimica et Biophysica Sinica. - 2018. - Т. 50. - N. 4. - С. 355 - 361.